PDS Biotechnology to be added to Russell 2000, Russell 3000 indexes

PDS Biotechnology announced its expected addition to the broad-market Russell 2000 and the Russell 3000 Indexes in accordance with the 2023 Russell indexes annual reconstitution. PDS Biotech’s anticipated inclusion in the Russell indexes will be effective after the U.S. market opens on Monday, June 26, 2023. “The expected addition of PDS Biotech to the Russell indexes is the latest milestone during a year in which we have made considerable progress with our lead candidate, PDS0101, including the presentation of promising interim data from the VERSATILE-002 Phase 2 clinical trial at ASCO 2023, and expanded our product portfolio and clinical pipeline with the acquisition of PDS0301,” stated Dr. Frank Bedu-Addo, President and CEO of PDS Biotech. “The Russell indexes are widely used investment benchmarks for index funds and active portfolio strategies. Our inclusion is an important validation and should help our efforts to propel long-term shareholder value, expand awareness of PDS Biotech within the investment community, increase the liquidity of our stock, and broaden our shareholder base.”